S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

ASX:NOX - Noxopharm Stock Price, Forecast & News

A$0.25
-0.05 (-16.67 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
A$0.24
Now: A$0.25
A$0.29
50-Day Range
A$0.22
MA: A$0.26
A$0.31
52-Week Range
A$0.21
Now: A$0.25
A$0.74
Volume1.52 million shs
Average VolumeN/A
Market Capitalization$33.05 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It is developing Veyonda, a dosage formulation of idronoxil, a generic anti-cancer agent for the treatment of late-stage cancers. The company also focuses on developing NYX-104, a drug intended to protect the brain from excitotoxicity; NYX-205, a drug to treat inflammation of the nervous tissue; and NYX-330, a PCSK9-inhibitor developed as a companion product for statin drugs in lowering low density lipoprotein cholesterol levels in patients at risk of cardiovascular disease. Noxopharm Limited was incorporated in 2015 and is based in Gordon, Australia.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone61 2 9144 2223

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.75 million
Cash FlowA$0.02 per share
Book ValueA$0.00 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$33.05 million
Next Earnings DateN/A
OptionableNot Optionable

Receive NOX News and Ratings via Email

Sign-up to receive the latest news and ratings for NOX and its competitors with MarketBeat's FREE daily newsletter.


Noxopharm (ASX:NOX) Frequently Asked Questions

What is Noxopharm's stock symbol?

Noxopharm trades on the ASX under the ticker symbol "NOX."

How were Noxopharm's earnings last quarter?

Noxopharm Ltd (ASX:NOX) posted its quarterly earnings data on Thursday, February, 21st. The company reported ($0.04) earnings per share (EPS) for the quarter. View Noxopharm's Earnings History.

Has Noxopharm been receiving favorable news coverage?

Media headlines about NOX stock have trended very negative on Monday, InfoTrie Sentiment reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Noxopharm earned a news impact score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Noxopharm.

Who are some of Noxopharm's key competitors?

What other stocks do shareholders of Noxopharm own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Noxopharm investors own include Lincoln Educational Services (LINC), IMMURON LTD/S (IMRN) and Venture Minerals (VMS).

Who are Noxopharm's key executives?

Noxopharm's management team includes the folowing people:
  • Dr. Graham Edmund Kelly, Group CEO, MD & Director (Age 74)
  • Mr. David James Franks B.Ec, BEc, CA, F Fin, JP., Company Sec. (Age 49)
  • Dr. Greg van Wyk, CEO & Chief Medical Officer
  • Mr. Bhavin Raval, Chief Financial Officer
  • Dr. John Wilkinson, Chief Scientific Officer

What is Noxopharm's stock price today?

One share of NOX stock can currently be purchased for approximately A$0.25.

How big of a company is Noxopharm?

Noxopharm has a market capitalization of $33.05 million and generates $3.75 million in revenue each year. View Additional Information About Noxopharm.

What is Noxopharm's official website?

The official website for Noxopharm is http://www.noxopharm.com/.

How can I contact Noxopharm?

The company can be reached via phone at 61 2 9144 2223.


MarketBeat Community Rating for Noxopharm (ASX NOX)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  12 (Vote Outperform)
Underperform Votes:  15 (Vote Underperform)
Total Votes:  27
MarketBeat's community ratings are surveys of what our community members think about Noxopharm and other stocks. Vote "Outperform" if you believe NOX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NOX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel